Friday, January 18, 2019
Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse platform technology for antibody drug discovery, today announced the expansion of its existing non-exclusive perpetual license agreement with Eli Lilly and Company. The expanded rights will more broadly enable EIi Lilly to use the AlivaMab Mouse platform for projects with collaborators, including the right to grant sub-licenses to antibody drug candidates much earlier in discovery. Financial terms of the agreement include an undisclosed upfront payment from Eli Lilly. Any potential milestones and royalties on product sales would be paid by the sub-licensees of the AlivaMab Mouse platform.
“This agreement further advances Ablexis’ goal of making AlivaMab Mouse more broadly available for the discovery of the next generation of antibody-based therapeutics,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis and AlivaMab Discovery Services, LLC. “Within the span of just a few weeks the AlivaMab Mouse platform consistently delivers diverse panels of high-affinity, high-potency antibodies with favorable developability qualities and reduced chance of immunogenicity. This represents a significant advantage over in vitro display approaches or other transgenic animal platforms. We look forward to continue making AlivaMab Mouse the platform of choice for experienced antibody drug discoverers and developers.”
